CAIROLI, ROBERTO
 Distribuzione geografica
Continente #
EU - Europa 4.760
AS - Asia 4.164
NA - Nord America 2.919
SA - Sud America 295
AF - Africa 55
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.209
Nazione #
US - Stati Uniti d'America 2.844
RU - Federazione Russa 1.840
SG - Singapore 1.748
HK - Hong Kong 1.466
IT - Italia 1.036
IE - Irlanda 896
CN - Cina 536
DE - Germania 263
BR - Brasile 262
ID - Indonesia 187
SE - Svezia 141
GB - Regno Unito 125
FI - Finlandia 79
NL - Olanda 76
AT - Austria 71
IN - India 69
UA - Ucraina 51
ES - Italia 42
CA - Canada 38
FR - Francia 35
MX - Messico 28
JP - Giappone 27
ZA - Sudafrica 23
TR - Turchia 21
CH - Svizzera 18
AU - Australia 14
PH - Filippine 12
VN - Vietnam 12
BE - Belgio 11
MA - Marocco 10
TN - Tunisia 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
PL - Polonia 9
CO - Colombia 8
HR - Croazia 8
SA - Arabia Saudita 8
AR - Argentina 7
BD - Bangladesh 7
CL - Cile 7
GR - Grecia 7
HU - Ungheria 7
KR - Corea 7
NP - Nepal 7
TW - Taiwan 7
IL - Israele 6
IR - Iran 6
PK - Pakistan 6
UZ - Uzbekistan 6
EG - Egitto 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
PT - Portogallo 4
RO - Romania 4
TH - Thailandia 4
IQ - Iraq 3
JO - Giordania 3
LT - Lituania 3
NO - Norvegia 3
AM - Armenia 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GE - Georgia 2
KE - Kenya 2
NI - Nicaragua 2
PE - Perù 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UG - Uganda 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GH - Ghana 1
GT - Guatemala 1
JM - Giamaica 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
UY - Uruguay 1
Totale 12.209
Città #
Hong Kong 1.460
Singapore 1.187
Dublin 845
Santa Clara 404
New York 402
Milan 279
Hefei 233
Ashburn 204
Moscow 191
Jakarta 171
Ann Arbor 124
Beijing 118
Nuremberg 88
Turin 88
Frankfurt am Main 80
Seattle 60
Shanghai 51
Rome 49
Fairfield 46
São Paulo 44
Helsinki 43
Chandler 41
Desio 41
Los Angeles 40
Boardman 34
London 33
Vienna 31
Amsterdam 26
Washington 25
Houston 22
Munich 21
Jacksonville 19
Lappeenranta 18
Princeton 18
Wilmington 18
Kilburn 17
Madrid 17
Assago 16
Dearborn 16
Naples 16
Bologna 14
Cinisello Balsamo 14
Phoenix 14
Cambridge 13
Hyderabad 13
Woodbridge 13
Mumbai 12
Turku 12
Guadalajara 11
Montreal 10
Nanjing 10
Rio de Janeiro 10
Altamura 9
Aurora 9
Lawrence 9
Manila 9
Paris 9
San Diego 9
Tokyo 9
Boston 8
Brescia 8
Brooklyn 8
Brussels 8
Carate Brianza 8
Chiswick 8
Genoa 8
Verona 8
Chicago 7
Dallas 7
Debrecen 7
Delhi 7
Florence 7
Istanbul 7
Orbassano 7
San Francisco 7
Toronto 7
Villongo 7
Zagreb 7
Ankara 6
Belo Horizonte 6
Changsha 6
Council Bluffs 6
Kolkata 6
Mexico City 6
New Delhi 6
Prague 6
Santa Monica 6
Tel Aviv 6
Tunis 6
Warsaw 6
Brugherio 5
Chengdu 5
Corsico 5
Guangzhou 5
Melbourne 5
Melzo 5
Palermo 5
Rocca Canavese 5
San Jose 5
Shijiazhuang 5
Totale 7.108
Nome #
Assessing eligibility for treatment in acute myeloid leukemia in 2023 311
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 228
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 175
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 168
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 154
Impact of serial echocardiography in the management of primary cardiac lymphoma 145
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 125
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 117
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 104
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 95
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 86
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 85
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 84
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 79
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 79
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 78
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 76
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 75
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 71
Lymphoma’s last therapeutic option: Freeze it! 71
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 64
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 63
MIS-A: Beware of non-lymphoma 62
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 62
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 62
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 61
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 61
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 60
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 59
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 58
Myeloma’s multiple morphologies 56
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 56
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 56
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 56
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 56
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 56
Arg expression studied in normal human leukocytes and in leukemic cells by RT-PCR 54
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 53
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 53
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 53
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 53
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 53
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 52
c-kit activating mutations and mast cell proliferation in human leukemia [4] 52
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 51
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 51
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 50
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 50
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 50
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 50
Fungal infections in hematologic neoplasms: Autopsy findings 50
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 50
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 49
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 47
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 47
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 47
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index 47
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 47
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 47
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 47
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 46
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 46
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 46
Hypoplasia of the Spleen: Rare and Puzzling 46
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 46
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 45
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 45
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 45
CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBINATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE MYELOID LEUKEMIA 45
LABNET AML: AN EFFICIENT NETWORK THAT CONNECTS HEMATOLOGY CENTERS AND LABORATORIES FOR A HIGH-LEVEL DIAGNOSTIC/PROGNOSTIC WORKUP OF AML 44
Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda” 44
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 43
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 43
Prospective clinical study on extracorporeal photopheresis (ECP) as prophylaxis for chronic Graft Versus Host Disease (cGVHD) prophylaxis: an interim analysis 43
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 43
Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience 43
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 43
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial 43
Gastrointestinal Kaposi's Sarcoma in a Woman with Selective IgA Deficiency and prior Immunosuppressive therapy for Idiopathic Thrombocitopenioc Purpura 43
ACUTE PROMYELOCYTIC LEUKEMIA - COMPLETE REMISSION AND BONE-MARROW TRANSPLANTATION FOLLOW-UP MONITORED BY POLYMERASE CHAIN-REACTION 43
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 43
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 43
Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial (Experimental Hematology & Oncology, (2021), 10, 1, (14), 10.1186/s40164-021-00210-9) 43
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 42
Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience 42
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 42
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 42
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 42
High dose etoposide and cyclophosphamide (HD-VP/CTX) as salvage treatment for all patients 42
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 41
Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with INV(16) 41
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy 41
Quantification of BCR/ABL transcript in mobilized cells of CML patients 41
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 41
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 41
New Insights from CAR-T: An Economic and Organizational Perspective 41
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 40
Complications at insertion of untunnelled central venous catheters (UCVCs) in leukemic patients at a high risk of hemorrhage 40
Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment 40
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL) 40
Totale 6.270
Categoria #
all - tutte 86.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.239


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 0 0 0 0 4 3
2020/2021141 3 3 40 14 15 11 12 12 14 6 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20257.519 545 1.184 457 439 783 295 687 221 844 1.048 1.016 0
Totale 13.202